A novel way to quantify schizophrenia symptoms in clinical trials
Version 3 2024-06-18, 22:59
Version 2 2024-06-06, 09:26
Version 1 2020-09-21, 15:47
journal contribution
posted on 2024-06-18, 22:59 authored by ON Medvedev, Michael BerkMichael Berk, Olivia DeanOlivia Dean, E Brown, MH Sandham, JF Dipnall, RK McNamara, A Sumich, CU Krägeloh, A Narayanan, RJ SiegertA novel way to quantify schizophrenia symptoms in clinical trials
History
Journal
European Journal of Clinical InvestigationVolume
51Article number
ARTN e13398Pagination
1 - 8Location
EnglandPublisher DOI
Open access
- Yes
Link to full text
ISSN
0014-2972eISSN
1365-2362Language
EnglishPublication classification
C1 Refereed article in a scholarly journalIssue
3Publisher
WILEYUsage metrics
Keywords
Science & TechnologyLife Sciences & BiomedicineMedicine, General & InternalMedicine, Research & ExperimentalGeneral & Internal MedicineResearch & Experimental Medicineclinical trialgeneralizability theorymeasurementpositive and negative syndrome scaleschizophreniaNEGATIVE-SYNDROME-SCALEGENERALIZABILITY THEORYPANSSTRANSIENTMETAANALYSISVALIDATIONIMPACTTIME110999 Neurosciences not elsewhere classified920410 Mental HealthSchool of MedicineFaculty of HealthInstitute for Innovation in Mental and Physical Health and Clinical Translation3209 Neurosciences3202 Clinical sciences420313 Mental health services200409 Mental health
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC